Progression of kidney disease in moderately hypercholesterolemic, hypertensive patients randomized to pravastatin versus usual care: a report from the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT).

ABSTRACT:

Background

Dyslipidemia is common in patients with chronic kidney disease. The role of statin therapy in the progression of kidney disease is unclear.

Study design

Prospective randomized clinical trial, post hoc analyses.

Setting & participants

10,060 participants in the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (lipid-lowering component) stratified by baseline estimated glomerular filtration rate (eGFR): less than 60, 60 to 89, and 90 or greater mL/min/1.73 m(2). Mean follow-up was 4.8 years.

Intervention

Randomized; pravastatin, 40 mg/d, or usual care.

Outcomes & measurements

Total, high-density lipoprotein, and low-density lipoprotein cholesterol; end-stage renal disease (ESRD), eGFR.

Results

Through year 6, to

SUBMITTER: Rahman M 

PROVIDER: S-EPMC2897819 | biostudies-literature | 2008 Sep

REPOSITORIES: biostudies-literature